GSK plc with ticker (LON:GSK) now has a potential downside of -4.2% according to JP Morgan.
JP Morgan set a target price of 1,660 GBX for the company, which when compared to the GSK plc share price of 1,733 GBX at opening today (03/05/2024) indicates a potential downside of -4.2%. Trading has ranged between 1,303 (52 week low) and 1,743 (52 week high) with an average of 5,117,084 shares exchanging hands daily. The market capitalisation at the time of writing is £71,443,796,655.
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
GSK plc -4.2% potential downside indicated by JP Morgan
- Written by: Charlotte Edwards
Latest Company News
GSK has announced that the EMA’s CHMP has recommended broadening the indication of its adjuvanted RSV vaccine to adults aged 18 and over, with a final decision expected in February 2026.
GSK has announced that its B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, has been granted Orphan Drug Designation by the US FDA for small-cell lung cancer.
TESARO, part of GSK, has filed a case in the Delaware Chancery Court claiming AnaptysBio has breached its licence agreement for the cancer treatment Jemperli.
GSK reported Q3 2025 sales of £8.5 billion, up 8% at constant exchange rates, driven by strong performances across Specialty Medicines, Vaccines and General Medicines.
GSK has announced that its B7-H3-targeted antibody-drug conjugate, GSK5764227 (GSK'227), has been granted Orphan Drug Designation by the European Medicines Agency for treating pulmonary neuroendocrine carcinoma, including small-cell lung cancer.
GSK has received FDA approval for Blenrep (belantamab mafodotin-blmf) with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least two prior therapies.
